Context-dependent roles for lymphotoxin-beta receptor signaling in cancer development.

[en] The LTalpha1beta2 and LIGHT TNF superfamily cytokines exert pleiotropic physiological functions through the activation of their cognate lymphotoxin-beta receptor (LTbetaR). Interestingly, since the discovery of these proteins, accumulating evidence has pinpointed a role for LTbetaR signaling in carcinogenesis. Early studies have shown a potential anti-tumoral role in a subset of solid cancers either by triggering apoptosis in malignant cells or by eliciting an anti-tumor immune response. However, more recent studies provided robust evidence that LTbetaR signaling is also involved in diverse cell-intrinsic and microenvironment-dependent pro-oncogenic mechanisms, affecting several solid and hematological malignancies. Consequently, the usefulness of LTbetaR signaling axis blockade has been investigated as a potential therapeutic approach for cancer. Considering the seemingly opposite roles of LTbetaR signaling in diverse cancer types and their key implications for therapy, we here extensively review the different mechanisms by which LTbetaR activation affects carcinogenesis, focusing on the diverse contexts and different models assessed.

Disciplines :

Biochemistry, biophysics & molecular biology

Author, co-author :

Fernandes, Monica T.

Dejardin, Emmanuel ; Université de Liège - ULiège

Santos, Nuno R. Dos

Language :

English

Title :

Context-dependent roles for lymphotoxin-beta receptor signaling in cancer development.

Publication date :

2016

Journal title :

Biochimica et Biophysica Acta

ISSN :

0006-3002

eISSN :

1878-2434

Publisher :

Elsevier, Amsterdam, Netherlands

Peer reviewed :

Peer Reviewed verified by ORBi

Commentary :

Available on ORBi :

since 11 March 2016

Statistics

Number of views

67 (8 by ULiège)

Number of downloads

1 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Fütterer A., Mink K., Luz A., Kosco-Vilbois M.H., Pfeffer K. The lymphotoxin beta receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues. Immunity 1998, 9:59-70.
Koni P.A., Sacca R., Lawton P., Browning J.L., Ruddle N.H., Flavell R.A. Distinct roles in lymphoid organogenesis for lymphotoxins alpha and beta revealed in lymphotoxin beta-deficient mice. Immunity 1997, 6:491-500.
De Togni P., Goellner J., Ruddle N.H., Streeter P.R., Fick A., Mariathasan S., et al. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 1994, 264:703-707.
Boehm T., Scheu S., Pfeffer K., Bleul C.C. Thymic medullary epithelial cell differentiation, thymocyte emigration, and the control of autoimmunity require lympho-epithelial cross talk via LTbetaR. J. Exp. Med. 2003, 198:757-769.
Tumanov A.V., Koroleva E.P., Christiansen P.A., Khan M.A., Ruddy M.J., Burnette B., et al. T cell-derived lymphotoxin regulates liver regeneration. Gastroenterology 2009, 136:694-704.
Lo J.C., Wang Y., Tumanov A.V., Bamji M., Yao Z., Reardon C.A., et al. Lymphotoxin beta receptor-dependent control of lipid homeostasis. Science 2007, 316:285-288.
Browning J.L., Allaire N., Ngam-Ek A., Notidis E., Hunt J., Perrin S., et al. Lymphotoxin-beta receptor signaling is required for the homeostatic control of HEV differentiation and function. Immunity 2005, 23:539-550.
Hu D., Mohanta S.K., Yin C., Peng L., Ma Z., Srikakulapu P., et al. Artery tertiary lymphoid organs control aorta immunity and protect against atherosclerosis via vascular smooth muscle cell lymphotoxin β receptors. Immunity 2015, 42:1100-1115.
Bekiaris V., Šedy J.R., Rossetti M., Spreafico R., Sharma S., Rhode-Kurnow A., et al. Human CD4+CD3- innate-like T cells provide a source of TNF and lymphotoxin-αβ and are elevated in rheumatoid arthritis. J. Immunol. 2013, 191:4611-4618.
Young J., Yu X., Wolslegel K., Nguyen A., Kung C., Chiang E., et al. Lymphotoxin-alphabeta heterotrimers are cleaved by metalloproteinases and contribute to synovitis in rheumatoid arthritis. Cytokine 2010, 51:78-86.
Gatumu M.K., Skarstein K., Papandile A., Browning J.L., Fava R.A., Bolstad A.I. Blockade of lymphotoxin-beta receptor signaling reduces aspects of Sjögren's syndrome in salivary glands of non-obese diabetic mice. Arthritis Res. Ther. 2009, 11:R24.
Seleznik G.M., Zoller J., O'Connor T., Graf R., Heikenwalder M. The role of lymphotoxin signaling in the development of autoimmune pancreatitis and associated secondary extra-pancreatic pathologies. Cytokine Growth Factor Rev. 2014, 25:125-137.
Haybaeck J., Zeller N., Wolf M.J., Weber A., Wagner U., Kurrer M.O., et al. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 2009, 16:295-308.
Stopfer P., Männel D.N., Hehlgans T. Lymphotoxin-beta receptor activation by activated T cells induces cytokine release from mouse bone marrow-derived mast cells. J. Immunol. 2004, 172:7459-7465.
Drutskaya M.S., Efimov G.A., Kruglov A.A., Kuprash D.V., Nedospasov S.A. Tumor necrosis factor, lymphotoxin and cancer. IUBMB Life. 2010, 62:283-289.
Wolf M.J., Seleznik G.M., Zeller N., Heikenwalder M. The unexpected role of lymphotoxin beta receptor signaling in carcinogenesis: from lymphoid tissue formation to liver and prostate cancer development. Oncogene 2010, 29:5006-5018.
Crowe P.D., VanArsdale T.L., Walter B.N., Ware C.F., Hession C., Ehrenfels B., et al. A lymphotoxin-beta-specific receptor. Science 1994, 264:707-710.
Force W.R., Walter B.N., Hession C., Tizard R., Kozak C.A., Browning J.L., et al. Mouse lymphotoxin-beta receptor. Molecular genetics, ligand binding, and expression. J. Immunol. 1995, 155:5280-5288.
Ganeff C., Remouchamps C., Boutaffala L., Benezech C., Galopin G., Vandepaer S., et al. Induction of the alternative NF-κB pathway by lymphotoxin αβ (LTαβ) relies on internalization of LTβ receptor. Mol. Cell. Biol. 2011, 31:4319-4334.
Kuai J., Nickbarg E., Wooters J., Qiu Y., Wang J., Lin L.-L. Endogenous association of TRAF2, TRAF3, cIAP1, and Smac with lymphotoxin beta receptor reveals a novel mechanism of apoptosis. J. Biol. Chem. 2003, 278:14363-14369.
VanArsdale T.L., VanArsdale S.L., Force W.R., Walter B.N., Mosialos G., Kieff E., et al. Lymphotoxin-beta receptor signaling complex: role of tumor necrosis factor receptor-associated factor 3 recruitment in cell death and activation of nuclear factor kappaB. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:2460-2465.
Krajewska M., Krajewski S., Zapata J.M., Van Arsdale T., Gascoyne R.D., Berern K., et al. TRAF-4 expression in epithelial progenitor cells. Analysis in normal adult, fetal, and tumor tissues. Am. J. Pathol. 1998, 152:1549-1561.
Nakano H., Oshima H., Chung W., Williams-Abbott L., Ware C.F., Yagita H., et al. TRAF5, an activator of NF-kappaB and putative signal transducer for the lymphotoxin-beta receptor. J. Biol. Chem. 1996, 271:14661-14664.
Force W.R., Glass A.A., Benedict C.A., Cheung T.C., Lama J., Ware C.F. Discrete signaling regions in the lymphotoxin-beta receptor for tumor necrosis factor receptor-associated factor binding, subcellular localization, and activation of cell death and NF-kappaB pathways. J. Biol. Chem. 2000, 275:11121-11129.
Murphy M., Walter B.N., Pike-Nobile L., Fanger N.A., Guyre P.M., Browning J.L., et al. Expression of the lymphotoxin beta receptor on follicular stromal cells in human lymphoid tissues. Cell Death Differ. 1998, 5:497-505.
Seach N., Ueno T., Fletcher A.L., Lowen T., Mattesich M., Engwerda C.R., et al. The lymphotoxin pathway regulates Aire-independent expression of ectopic genes and chemokines in thymic stromal cells. J. Immunol. 2008, 180:5384-5392.
Browning J.L., Sizing I.D., Lawton P., Bourdon P.R., Rennert P.D., Majeau G.R., et al. Characterization of lymphotoxin-alpha beta complexes on the surface of mouse lymphocytes. J. Immunol. 1997, 159:3288-3298.
Mauri D.N., Ebner R., Montgomery R.I., Kochel K.D., Cheung T.C., Yu G.L., et al. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity 1998, 8:21-30.
Ware C.F., Crowe P.D., Grayson M.H., Androlewicz M.J., Browning J.L. Expression of surface lymphotoxin and tumor necrosis factor on activated T, B, and natural killer cells. J. Immunol. 1992, 149:3881-3888.
Browning J.L., Ngam-ek A., Lawton P., DeMarinis J., Tizard R., Chow E.P., et al. Lymphotoxin beta, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface. Cell 1993, 72:847-856.
Lawton P., Nelson J., Tizard R., Browning J.L. Characterization of the mouse lymphotoxin-beta gene. J. Immunol. 1995, 154:239-246.
Nedospasov S.A., Hirt B., Shakhov A.N., Dobrynin V.N., Kawashima E., Accolla R.S., et al. The genes for tumor necrosis factor (TNF-alpha) and lymphotoxin (TNF-beta) are tandemly arranged on chromosome 17 of the mouse. Nucleic Acids Res. 1986, 14:7713-7725.
Nedwin G.E., Naylor S.L., Sakaguchi A.Y., Smith D., Jarrett-Nedwin J., Pennica D., et al. Human lymphotoxin and tumor necrosis factor genes: structure, homology and chromosomal localization. Nucleic Acids Res. 1985, 13:6361-6373.
Eck M.J., Ultsch M., Rinderknecht E., de Vos A.M., Sprang S.R. The structure of human lymphotoxin (tumor necrosis factor-beta) at 1.9-A resolution. J. Biol. Chem. 1992, 267:2119-2122.
Williams-Abbott L., Walter B.N., Cheung T.C., Goh C.R., Porter A.G., Ware C.F. The lymphotoxin-alpha (LTalpha) subunit is essential for the assembly, but not for the receptor specificity, of the membrane-anchored LTalpha1beta2 heterotrimeric ligand. J. Biol. Chem. 1997, 272:19451-19456.
Androlewicz M.J., Browning J.L., Ware C.F. Lymphotoxin is expressed as a heteromeric complex with a distinct 33-kDa glycoprotein on the surface of an activated human T cell hybridoma. J. Biol. Chem. 1992, 267:2542-2547.
Browning J.L., Dougas I., Ngam-ek A., Bourdon P.R., Ehrenfels B.N., Miatkowski K., et al. Characterization of surface lymphotoxin forms. Use of specific monoclonal antibodies and soluble receptors. J. Immunol. 1995, 154:33-46.
Kuprash D.V., Boitchenko V.E., Yarovinsky F.O., Rice N.R., Nordheim A., Rühlmann A., et al. Cyclosporin A blocks the expression of lymphotoxin alpha, but not lymphotoxin beta, in human peripheral blood mononuclear cells. Blood 2002, 100:1721-1727.
Millet I., Ruddle N.H. Differential regulation of lymphotoxin (LT), lymphotoxin-beta (LT-beta), and TNF-alpha in murine T cell clones activated through the TCR. J. Immunol. 1994, 152:4336-4346.
De Trez C., Schneider K., Potter K., Droin N., Fulton J., Norris P.S., et al. The inhibitory HVEM-BTLA pathway counter regulates lymphotoxin receptor signaling to achieve homeostasis of dendritic cells. J. Immunol. 2008, 180:238-248.
Cupedo T., Jansen W., Kraal G., Mebius R.E. Induction of secondary and tertiary lymphoid structures in the skin. Immunity 2004, 21:655-667.
Luther S.A., Bidgol A., Hargreaves D.C., Schmidt A., Xu Y., Paniyadi J., et al. Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J. Immunol. 2002, 169:424-433.
Simonin Y., Vegna S., Akkari L., Grégoire D., Antoine E., Piette J., et al. Lymphotoxin signaling is initiated by the viral polymerase in HCV-linked tumorigenesis. PLoS Pathog. 2013, 9.
Kim D.-H., Kim E.-M., Lee E.-H., Ji K.-Y., Yi J., Park M., et al. Human papillomavirus 16E6 suppresses major histocompatibility complex class I by upregulating lymphotoxin expression in human cervical cancer cells. Biochem. Biophys. Res. Commun. 2011, 409:792-798.
Granger S.W., Butrovich K.D., Houshmand P., Edwards W.R., Ware C.F. Genomic characterization of LIGHT reveals linkage to an immune response locus on chromosome 19p13.3 and distinct isoforms generated by alternate splicing or proteolysis. J. Immunol. 2001, 167:5122-5128.
Misawa K., Nosaka T., Kojima T., Hirai M., Kitamura T. Molecular cloning and characterization of a mouse homolog of human TNFSF14, a member of the TNF superfamily. Cytogenet. Cell Genet. 2000, 89:89-91.
Tamada K., Shimozaki K., Chapoval A.I., Zhai Y., Su J., Chen S.F., et al. LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J. Immunol. 2000, 164:4105-4110.
Zhai Y., Guo R., Hsu T.L., Yu G.L., Ni J., Kwon B.S., et al. LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J. Clin. Invest. 1998, 102:1142-1151.
Cohavy O., Zhou J., Ware C.F., Targan S.R. LIGHT is constitutively expressed on T and NK cells in the human gut and can be induced by CD2-mediated signaling. J. Immunol. 2005, 174:646-653.
Bossen C., Ingold K., Tardivel A., Bodmer J.-L., Gaide O., Hertig S., et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J. Biol. Chem. 2006, 281:13964-13971.
Chaplin D.D., Fu Y. Cytokine regulation of secondary lymphoid organ development. Curr. Opin. Immunol. 1998, 10:289-297.
Kwon B.S., Tan K.B., Ni J., Oh K.O., Lee Z.H., Kim K.K., et al. A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J. Biol. Chem. 1997, 272:14272-14276.
Yu K.Y., Kwon B., Ni J., Zhai Y., Ebner R., Kwon B.S. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J. Biol. Chem. 1999, 274:13733-13736.
Pierer M., Brentano F., Rethage J., Wagner U., Hantzschel H., Gay R.E., et al. The TNF superfamily member LIGHT contributes to survival and activation of synovial fibroblasts in rheumatoid arthritis. Rheumatol. 2007, 46:1063-1070.
Murphy T.L., Murphy K.M. Slow down and survive: enigmatic immunoregulation by BTLA and HVEM. Annu. Rev. Immunol. 2010, 28:389-411.
Cheung T.C., Steinberg M.W., Oborne L.M., Macauley M.G., Fukuyama S., Sanjo H., et al. Unconventional ligand activation of herpesvirus entry mediator signals cell survival. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:6244-6249.
Morel Y., Schiano de Colella J.M., Harrop J., Deen K.C., Holmes S.D., Wattam T.A., et al. Reciprocal expression of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T cells: LIGHT down-regulates its own receptor. J. Immunol. 2000, 165:4397-4404.
Shi G., Luo H., Wan X., Salcedo T.W., Zhang J., Wu J. Mouse T cells receive costimulatory signals from LIGHT, a TNF family member. Blood 2002, 100:3279-3286.
Wan X., Zhang J., Luo H., Shi G., Kapnik E., Kim S., et al. A TNF family member LIGHT transduces costimulatory signals into human T cells. J. Immunol. 2002, 169:6813-6821.
Banner D.W., D'Arcy A., Janes W., Gentz R., Schoenfeld H.J., Broger C., et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 1993, 73:431-445.
Sudhamsu J., Yin J., Chiang E.Y., Starovasnik M.A., Grogan J.L., Hymowitz S.G. Dimerization of LTβR by LTα1β2 is necessary and sufficient for signal transduction. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:19896-19901.
Eldredge J., Berkowitz S., Corin A.F., Day E.S., Hayes D., Meier W., et al. Stoichiometry of LTbetaR binding to LIGHT. Biochemistry (Mosc) 2006, 45:10117-10128.
Norris P.S., Ware C.F. The LT beta R signaling pathway. Adv. Exp. Med. Biol. 2007, 597:160-172.
Mackay F., Majeau G.R., Hochman P.S., Browning J.L. Lymphotoxin beta receptor triggering induces activation of the nuclear factor kappaB transcription factor in some cell types. J. Biol. Chem. 1996, 271:24934-24938.
Dhawan P., Su Y., Thu Y.M., Yu Y., Baugher P., Ellis D.L., et al. The lymphotoxin-beta receptor is an upstream activator of NF-kappaB-mediated transcription in melanoma cells. J. Biol. Chem. 2008, 283:15399-15408.
Wu M.Y., Wang P.Y., Han S.H., Hsieh S.L. The cytoplasmic domain of the lymphotoxin-beta receptor mediates cell death in HeLa cells. J. Biol. Chem. 1999, 274:11868-11873.
Chang Y.-H., Hsieh S.-L., Chen M.-C., Lin W.-W. Lymphotoxin beta receptor induces interleukin 8 gene expression via NF-kappaB and AP-1 activation. Exp. Cell Res. 2002, 278:166-174.
Kim Y.-S., Nedospasov S.A., Liu Z.-G. TRAF2 plays a key, nonredundant role in LIGHT-lymphotoxin beta receptor signaling. Mol. Cell. Biol. 2005, 25:2130-2137.
Browning J.L., Miatkowski K., Sizing I., Griffiths D., Zafari M., Benjamin C.D., et al. Signaling through the lymphotoxin beta receptor induces the death of some adenocarcinoma tumor lines. J. Exp. Med. 1996, 183:867-878.
Lukashev M., LePage D., Wilson C., Bailly V., Garber E., Lukashin A., et al. Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy. Cancer Res. 2006, 66:9617-9624.
Chen M.C., Hsu T.L., Luh T.Y., Hsieh S.L. Overexpression of bcl-2 enhances LIGHT- and interferon-gamma -mediated apoptosis in Hep3BT2 cells. J. Biol. Chem. 2000, 275:38794-38801.
Chen M.-C., Hwang M.-J., Chou Y.-C., Chen W.-H., Cheng G., Nakano H., et al. The role of apoptosis signal-regulating kinase 1 in lymphotoxin-beta receptor-mediated cell death. J. Biol. Chem. 2003, 278:16073-16081.
Hu X., Zimmerman M.A., Bardhan K., Yang D., Waller J.L., Liles G.B., et al. Lymphotoxin β receptor mediates caspase-dependent tumor cell apoptosis in vitro and tumor suppression in vivo despite induction of NF-κB activation. Carcinogenesis 2013, 34:1105-1114.
Wilson C.A., Browning J.L. Death of HT29 adenocarcinoma cells induced by TNF family receptor activation is caspase-independent and displays features of both apoptosis and necrosis. Cell Death Differ. 2002, 9:1321-1333.
Heikenwalder M., Prinz M., Zeller N., Lang K.S., Junt T., Rossi S., et al. Overexpression of lymphotoxin in T cells induces fulminant thymic involution. Am. J. Pathol. 2008, 172:1555-1570.
Liepinsh D.J., Kruglov A.A., Galimov A.R., Shakhov A.N., Shebzukhov Y.V., Kuchmiy A.A., et al. Accelerated thymic atrophy as a result of elevated homeostatic expression of the genes encoded by the TNF/lymphotoxin cytokine locus. Eur. J. Immunol. 2009, 39:2906-2915.
Boutaffala L., Bertrand M.J.M., Remouchamps C., Seleznik G., Reisinger F., Janas M., et al. NIK promotes tissue destruction independently of the alternative NF-κB pathway through TNFR1/RIP1-induced apoptosis. Cell Death Differ. 2015, 22:2020-2033.
Dejardin E., Droin N.M., Delhase M., Haas E., Cao Y., Makris C., et al. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 2002, 17:525-535.
Bista P., Zeng W., Ryan S., Bailly V., Browning J.L., Lukashev M.E. TRAF3 controls activation of the canonical and alternative NFkappaB by the lymphotoxin beta receptor. J. Biol. Chem. 2010, 285:12971-12978.
Müller J.R., Siebenlist U. Lymphotoxin beta receptor induces sequential activation of distinct NF-kappa B factors via separate signaling pathways. J. Biol. Chem. 2003, 278:12006-12012.
Vallabhapurapu S., Matsuzawa A., Zhang W., Tseng P.-H., Keats J.J., Wang H., et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat. Immunol. 2008, 9:1364-1370.
Zarnegar B.J., Wang Y., Mahoney D.J., Dempsey P.W., Cheung H.H., He J., et al. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat. Immunol. 2008, 9:1371-1378.
Sanjo H., Zajonc D.M., Braden R., Norris P.S., Ware C.F. Allosteric regulation of the ubiquitin:NIK and ubiquitin:TRAF3 E3 ligases by the lymphotoxin-beta receptor. J. Biol. Chem. 2010, 285:17148-17155.
Razani B., Zarnegar B., Ytterberg A.J., Shiba T., Dempsey P.W., Ware C.F., et al. Negative feedback in noncanonical NF-kappaB signaling modulates NIK stability through IKKalpha-mediated phosphorylation. Sci. Signal. 2010, 3.
Liao G., Zhang M., Harhaj E.W., Sun S.-C. Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J. Biol. Chem. 2004, 279:26243-26250.
Basak S., Kim H., Kearns J.D., Tergaonkar V., O'Dea E., Werner S.L., et al. A fourth IkappaB protein within the NF-kappaB signaling module. Cell 2007, 128:369-381.
Madge L.A., Kluger M.S., Orange J.S., May M.J. Lymphotoxin-alpha 1 beta 2 and LIGHT induce classical and noncanonical NF-kappa B-dependent proinflammatory gene expression in vascular endothelial cells. J. Immunol. 2008, 180:3467-3477.
Ettinger R., Browning J.L., Michie S.A., van Ewijk W., McDevitt H.O. Disrupted splenic architecture, but normal lymph node development in mice expressing a soluble lymphotoxin-beta receptor-IgG1 fusion protein. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:13102-13107.
Rennert P.D., Browning J.L., Mebius R., Mackay F., Hochman P.S. Surface lymphotoxin alpha/beta complex is required for the development of peripheral lymphoid organs. J. Exp. Med. 1996, 184:1999-2006.
Scheu S., Alferink J., Pötzel T., Barchet W., Kalinke U., Pfeffer K. Targeted disruption of LIGHT causes defects in costimulatory T cell activation and reveals cooperation with lymphotoxin beta in mesenteric lymph node genesis. J. Exp. Med. 2002, 195:1613-1624.
Banks T.A., Rouse B.T., Kerley M.K., Blair P.J., Godfrey V.L., Kuklin N.A., et al. Lymphotoxin-alpha-deficient mice. Effects on secondary lymphoid organ development and humoral immune responsiveness. J. Immunol. 1995, 155:1685-1693.
Alimzhanov M.B., Kuprash D.V., Kosco-Vilbois M.H., Luz A., Turetskaya R.L., Tarakhovsky A., et al. Abnormal development of secondary lymphoid tissues in lymphotoxin beta-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:9302-9307.
Kabashima K., Banks T.A., Ansel K.M., Lu T.T., Ware C.F., Cyster J.G. Intrinsic lymphotoxin-beta receptor requirement for homeostasis of lymphoid tissue dendritic cells. Immunity 2005, 22:439-450.
Wang Y.-G., Kim K.D., Wang J., Yu P., Fu Y.-X. Stimulating lymphotoxin beta receptor on the dendritic cells is critical for their homeostasis and expansion. J. Immunol. 2005, 175:6997-7002.
Banks T.A., Rickert S., Benedict C.A., Ma L., Ko M., Meier J., et al. A lymphotoxin-IFN-beta axis essential for lymphocyte survival revealed during cytomegalovirus infection. J. Immunol. 2005, 174:7217-7225.
Elewaut D., Brossay L., Santee S.M., Naidenko O.V., Burdin N., De Winter H., et al. Membrane lymphotoxin is required for the development of different subpopulations of NK T cells. J. Immunol. 2000, 165:671-679.
Silva-Santos B., Pennington D.J., Hayday A.C. Lymphotoxin-mediated regulation of gammadelta cell differentiation by alphabeta T cell progenitors. Science 2005, 307:925-928.
Wang J., Fu Y.-X. LIGHT (a cellular ligand for herpes virus entry mediator and lymphotoxin receptor)-mediated thymocyte deletion is dependent on the interaction between TCR and MHC/self-peptide. J. Immunol. 2003, 170:3986-3993.
Chai Q., Onder L., Scandella E., Gil-Cruz C., Perez-Shibayama C., Cupovic J., et al. Maturation of lymph node fibroblastic reticular cells from myofibroblastic precursors is critical for antiviral immunity. Immunity 2013, 38:1013-1024.
Zhao L., Liu L., Gao J., Yang Y., Hu C., Guo B., et al. T lymphocytes maintain structure and function of fibroblastic reticular cells via lymphotoxin (LT)-B. BMC Immunol. 2014, 15:33.
Tumanov A., Kuprash D., Lagarkova M., Grivennikov S., Abe K., Shakhov A., et al. Distinct role of surface lymphotoxin expressed by B cells in the organization of secondary lymphoid tissues. Immunity 2002, 17:239-250.
Ansel K.M., Ngo V.N., Hyman P.L., Luther S.A., Förster R., Sedgwick J.D., et al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 2000, 406:309-314.
Kratz A., Campos-Neto A., Hanson M.S., Ruddle N.H. Chronic inflammation caused by lymphotoxin is lymphoid neogenesis. J. Exp. Med. 1996, 183:1461-1472.
Onder L., Danuser R., Scandella E., Firner S., Chai Q., Hehlgans T., et al. Endothelial cell-specific lymphotoxin-β receptor signaling is critical for lymph node and high endothelial venule formation. J. Exp. Med. 2013, 210:465-473.
Mouri Y., Yano M., Shinzawa M., Shimo Y., Hirota F., Nishikawa Y., et al. Lymphotoxin signal promotes thymic organogenesis by eliciting RANK expression in the embryonic thymic stroma. J. Immunol. 2011, 186:5047-5057.
Anders R.A., Subudhi S.K., Wang J., Pfeffer K., Fu Y.-X. Contribution of the lymphotoxin beta receptor to liver regeneration. J. Immunol. 2005, 175:1295-1300.
Bénézech C., Mader E., Desanti G., Khan M., Nakamura K., White A., et al. Lymphotoxin-β receptor signaling through NF-κB2-RelB pathway reprograms adipocyte precursors as lymph node stromal cells. Immunity 2012, 37:721-734.
Ruddle N.H. Lymphotoxin and TNF: how it all began-a tribute to the travelers. Cytokine Growth Factor Rev. 2014, 25:83-89.
Yang D., Ud Din N., Browning D.D., Abrams S.I., Liu K. Targeting lymphotoxin beta receptor with tumor-specific T lymphocytes for tumor regression. Clin. Cancer Res. 2007, 13:5202-5210.
Kashii Y., Giorda R., Herberman R.B., Whiteside T.L., Vujanovic N.L. Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. J. Immunol. 1999, 163:5358-5366.
Lu G., Janjic B.M., Janjic J., Whiteside T.L., Storkus W.J., Vujanovic N.L. Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis-inducing ligand. J. Immunol. 2002, 168:1831-1839.
Winter H., van den Engel N.K., Poehlein C.H., Hatz R.A., Fox B.A., Hu H.-M. Tumor-specific T cells signal tumor destruction via the lymphotoxin beta receptor. J. Transl. Med. 2007, 5:14.
Yu P., Lee Y., Liu W., Chin R.K., Wang J., Wang Y., et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat. Immunol. 2004, 5:141-149.
Loeffler M., Le'Negrate G., Krajewska M., Reed J.C. Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:12879-12883.
Mortarini R., Scarito A., Nonaka D., Zanon M., Bersani I., Montaldi E., et al. Constitutive expression and costimulatory function of LIGHT/TNFSF14 on human melanoma cells and melanoma-derived microvesicles. Cancer Res. 2005, 65:3428-3436.
Yu P., Lee Y., Wang Y., Liu X., Auh S., Gajewski T.F., et al. Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J. Immunol. 2007, 179:1960-1968.
Hindley J.P., Jones E., Smart K., Bridgeman H., Lauder S.N., Ondondo B., et al. T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T-cell depletion. Cancer Res. 2012, 72:5473-5482.
Martinet L., Filleron T., Le Guellec S., Rochaix P., Garrido I., Girard J.-P. High endothelial venule blood vessels for tumor-infiltrating lymphocytes are associated with lymphotoxin β-producing dendritic cells in human breast cancer. J. Immunol. 2013.
Drayton D.L., Liao S., Mounzer R.H., Ruddle N.H. Lymphoid organ development: from ontogeny to neogenesis. Nat. Immunol. 2006, 7:344-353.
Martinet L., Le Guellec S., Filleron T., Lamant L., Meyer N., Rochaix P., et al. High endothelial venules (HEVs) in human melanoma lesions: major gateways for tumor-infiltrating lymphocytes. Oncoimmunology. 2012, 1:829-839.
Girard J.-P., Moussion C., Förster R. HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes. Nat. Rev. Immunol. 2012, 12:762-773.
Or Y.Y.-Y., Chung G.T.-Y., K.-F.To, Chow C., Choy K.-W., Tong C.Y.-K., et al. Identification of a novel 12p13.3 amplicon in nasopharyngeal carcinoma. J. Pathol. 2010, 220:97-107.
Fujiwara S., Yamashita Y., Choi Y.L., Wada T., Kaneda R., Takada S., et al. Transforming activity of the lymphotoxin-beta receptor revealed by expression screening. Biochem. Biophys. Res. Commun. 2005, 338:1256-1262.
Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.-J., et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007, 12:131-144.
Chung G.T.-Y., Lou W.P.-K., Chow C., K.-F.To, Choy K.-W., Leung A.W.-C., et al. Constitutive activation of distinct NF-κB signals in EBV-associated nasopharyngeal carcinoma. J. Pathol. 2013, 231:311-322.
Yang L., Feng R., Liu G., Liao M., Zhang L., Wang W. TNF-β +252 A > G polymorphism and susceptibility to cancer. J. Cancer Res. Clin. Oncol. 2013, 139:765-772.
Yu X., Huang Y., Li C., Yang H., Lu C., Duan S. Positive association between lymphotoxin-alpha variation rs909253 and cancer risk: a meta-analysis based on 36 case-control studies. Tumour Biol. 2014, 35:1973-1983.
Liu J., Liu J., Song B., Wang T., Liu Y., Hao J., et al. Genetic variations in CTLA-4, TNF-α, and LTA and susceptibility to T-cell lymphoma in a Chinese population. Cancer Epidemiol. 2013, 37:930-934.
Skibola C.F., Bracci P.M., Nieters A., Brooks-Wilson A., de Sanjosé S., Hughes A.M., et al. Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. Am. J. Epidemiol. 2010, 171:267-276.
Kohaar I., Tiwari P., Kumar R., Nasare V., Thakur N., Das B.C., et al. Association of single nucleotide polymorphisms (SNPs) in TNF-LTA locus with breast cancer risk in Indian population. Breast Cancer Res. Treat. 2009, 114:347-355.
Zhou P., Huang W., Chu X., Du L.-F., Li J.-P., Zhang C. The lymphotoxin-α 252 A > G polymorphism and breast cancer: a meta-analysis. Asian Pac. J. Cancer Prev. 2012, 13:1949-1952.
Lu R., Dou X., Gao X., Zhang J., Ni J., Guo L. A functional polymorphism of lymphotoxin-alpha (LTA) gene rs909253 is associated with gastric cancer risk in an Asian population. Cancer Epidemiol. 2012, 36:e380-e386.
Xu Z., Shi R., Zhang R., Zhang D., Wang L. Association between tumor necrosis factor β 252 A/G polymorphism and risk of gastric cancer: a meta-analysis. Tumour Biol. 2013, 34:4001-4005.
Messer G., Spengler U., Jung M.C., Honold G., Blömer K., Pape G.R., et al. Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J. Exp. Med. 1991, 173:209-219.
Ozaki K., Ohnishi Y., Iida A., Sekine A., Yamada R., Tsunoda T., et al. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat. Genet. 2002, 32:650-654.
Ware C.F. Network communications: lymphotoxins, LIGHT, and TNF. Annu. Rev. Immunol. 2005, 23:787-819.
Chovatiya R., Medzhitov R. Stress, inflammation, and defense of homeostasis. Mol. Cell 2014, 54:281-288.
Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
Daller B., Müsch W., Röhrl J., Tumanov A.V., Nedospasov S.A., Männel D.N., et al. Lymphotoxin-β receptor activation by lymphotoxin-α(1)β(2) and LIGHT promotes tumor growth in an NFκB-dependent manner. Int. J. Cancer 2011, 128:1363-1370.
Hehlgans T., Stoelcker B., Stopfer P., Müller P., Cernaianu G., Guba M., et al. Lymphotoxin-beta receptor immune interaction promotes tumor growth by inducing angiogenesis. Cancer Res. 2002, 62:4034-4040.
Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
Lucifora J., Xia Y., Reisinger F., Zhang K., Stadler D., Cheng X., et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014, 343:1221-1228.
Wolf M.J., Adili A., Piotrowitz K., Abdullah Z., Boege Y., Stemmer K., et al. Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell 2014, 26:549-564.
Scarzello A.J., Jiang Q., Back T., Dang H., Hodge D., Hanson C., et al. LTβR signalling preferentially accelerates oncogenic AKT-initiated liver tumours, Gut 2015, 10.1136/gutjnl-2014-308810.
Ammirante M., Luo J.-L., Grivennikov S., Nedospasov S., Karin M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 2010, 464:302-305.
He Y., Zha J., Wang Y., Liu W., Yang X., Yu P. Tissue damage-associated "danger signals" influence T-cell responses that promote the progression of preneoplasia to cancer. Cancer Res. 2013, 73:629-639.
Lau T.-S., Chung T.K.-H., Cheung T.-H., Chan L.K.-Y., Cheung L.W.-H., Yim S.-F., et al. Cancer cell-derived lymphotoxin mediates reciprocal tumour-stromal interactions in human ovarian cancer by inducing CXCL11 in fibroblasts. J. Pathol. 2014, 232:43-56.
Khan I.S., Mouchess M.L., Zhu M.-L., Conley B., Fasano K.J., Hou Y., et al. Enhancement of an anti-tumor immune response by transient blockade of central T cell tolerance. J. Exp. Med. 2014, 211:761-768.
Zhou P., Fang X., McNally B.A., Yu P., Zhu M., Fu Y.-X., et al. Targeting lymphotoxin-mediated negative selection to prevent prostate cancer in mice with genetic predisposition. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:17134-17139.
Annunziata C.M., Davis R.E., Demchenko Y., Bellamy W., Gabrea A., Zhan F., et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007, 12:115-130.
Rehm A., Mensen A., Schradi K., Gerlach K., Wittstock S., Winter S., et al. Cooperative function of CCR7 and lymphotoxin in the formation of a lymphoma-permissive niche within murine secondary lymphoid organs. Blood 2011, 118:1020-1033.
Heinig K., Gätjen M., Grau M., Stache V., Anagnostopoulos I., Gerlach K., et al. Access to follicular dendritic cells is a pivotal step in murine chronic lymphocytic leukemia B-cell activation and proliferation. Cancer Discov. 2014, 4:1448-1465.
Fernandes M.T., Ghezzo M.N., Silveira A.B., Kalathur R.K., Póvoa V., Ribeiro A.R., et al. Lymphotoxin-β receptor in microenvironmental cells promotes the development of T-cell acute lymphoblastic leukaemia with cortical/mature immunophenotype. Br. J. Haematol. 2015, 171:736-751.
dos Santos N.R., Williame M., Gachet S., Cormier F., Janin A., Weih D., et al. RelB-dependent stromal cells promote T-cell leukemogenesis. PLoS ONE 2008, 3.
Tournier C. The 2 faces of JNK signaling in cancer. Genes Cancer. 2013, 4:397-400.
Partheniou F., Kelsey S.M., Srinivasula S.M., Newland A.C., Alnemri E.S., Jia L. c-IAP1 blocks TNFalpha-mediated cytotoxicity upstream of caspase-dependent and -independent mitochondrial events in human leukemic cells. Biochem. Biophys. Res. Commun. 2001, 287:181-189.
Watanabe N., Niitsu Y., Umeno H., Kuriyama H., Neda H., Yamauchi N., et al. Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res. 1988, 48:2179-2183.
Polunovsky V.A., Wendt C.H., Ingbar D.H., Peterson M.S., Bitterman P.B. Induction of endothelial cell apoptosis by TNF alpha: modulation by inhibitors of protein synthesis. Exp. Cell Res. 1994, 214:584-594.
Palladino M.A., Shalaby M.R., Kramer S.M., Ferraiolo B.L., Baughman R.A., Deleo A.B., et al. Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity. J. Immunol. 1987, 138:4023-4032.
Blankenstein T., Qin Z.H., Uberla K., Müller W., Rosen H., Volk H.D., et al. Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer. J. Exp. Med. 1991, 173:1047-1052.
Baxevanis C.N., Voutsas I.F., Tsitsilonis O.E., Tsiatas M.L., Gritzapis A.D., Papamichail M. Compromised anti-tumor responses in tumor necrosis factor-alpha knockout mice. Eur. J. Immunol. 2000, 30:1957-1966.
Nakashima J., Tachibana M., Ueno M., Miyajima A., Baba S., Murai M. Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. Clin. Cancer Res. 1998, 4:1743-1748.
Ferrajoli A., Keating M.J., Manshouri T., Giles F.J., Dey A., Estrov Z., et al. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood 2002, 100:1215-1219.
Michalaki V., Syrigos K., Charles P., Waxman J. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br. J. Cancer 2004, 90:2312-2316.
Orosz P., Echtenacher B., Falk W., Rüschoff J., Weber D., Männel D.N. Enhancement of experimental metastasis by tumor necrosis factor. J. Exp. Med. 1993, 177:1391-1398.
Moore R.J., Owens D.M., Stamp G., Arnott C., Burke F., East N., et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat. Med. 1999, 5:828-831.
Suganuma M., Okabe S., Marino M.W., Sakai A., Sueoka E., Fujiki H. Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Res. 1999, 59:4516-4518.
Yan B., Wang H., Rabbani Z.N., Zhao Y., Li W., Yuan Y., et al. Tumor necrosis factor-alpha is a potent endogenous mutagen that promotes cellular transformation. Cancer Res. 2006, 66:11565-11570.
Popivanova B.K., Kitamura K., Wu Y., Kondo T., Kagaya T., Kaneko S., et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J. Clin. Invest. 2008, 118:560-570.
Mocellin S., Rossi C.R., Pilati P., Nitti D. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev. 2005, 16:35-53.
Bierie B., Moses H.L. Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev. 2010, 21:49-59.
Meulmeester E., Ten Dijke P. The dynamic roles of TGF-β in cancer. J. Pathol. 2011, 223:205-218.
Principe D.R., Doll J.A., Bauer J., Jung B., Munshi H.G., Bartholin L., et al. TGF-β: duality of function between tumor prevention and carcinogenesis. J. Natl. Cancer Inst. 2014, 106.
Bierie B., Moses H.L. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 2006, 6:506-520.
Bhowmick N.A., Chytil A., Plieth D., Gorska A.E., Dumont N., Shappell S., et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004, 303:848-851.
Yang L., Huang J., Ren X., Gorska A.E., Chytil A., Aakre M., et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1 + CD11b + myeloid cells that promote metastasis. Cancer Cell 2008, 13:23-35.
Gorelik L., Flavell R.A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat. Med. 2001, 7:1118-1122.
Yang Y.-A., Dukhanina O., Tang B., Mamura M., Letterio J.J., MacGregor J., et al. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J. Clin. Invest. 2002, 109:1607-1615.
Thomas D.A., Massagué J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005, 8:369-380.
Weng A.P., Ferrando A.A., Lee W., Morris J.P., Silverman L.B., Sanchez-Irizarry C., et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004, 306:269-271.
Di Ianni M., Baldoni S., Rosati E., Ciurnelli R., Cavalli L., Martelli M.F., et al. A new genetic lesion in B-CLL: a NOTCH1 PEST domain mutation. Br. J. Haematol. 2009, 146:689-691.
Kridel R., Meissner B., Rogic S., Boyle M., Telenius A., Woolcock B., et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood 2012, 119:1963-1971.
Robinson D.R., Kalyana-Sundaram S., Wu Y.-M., Shankar S., Cao X., Ateeq B., et al. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat. Med. 2011, 17:1646-1651.
Rossi D., Trifonov V., Fangazio M., Bruscaggin A., Rasi S., Spina V., et al. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J. Exp. Med. 2012, 209:1537-1551.
Kiel M.J., Velusamy T., Betz B.L., Zhao L., Weigelin H.G., Chiang M.Y., et al. Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J. Exp. Med. 2012, 209:1553-1565.
South A.P., Cho R.J., Aster J.C. The double-edged sword of Notch signaling in cancer. Semin. Cell Dev. Biol. 2012, 23:458-464.
Stransky N., Egloff A.M., Tward A.D., Kostic A.D., Cibulskis K., Sivachenko A., et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011, 333:1157-1160.
Agrawal N., Frederick M.J., Pickering C.R., Bettegowda C., Chang K., Li R.J., et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011, 333:1154-1157.
Wang N.J., Sanborn Z., Arnett K.L., Bayston L.J., Liao W., Proby C.M., et al. Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:17761-17766.
Klinakis A., Lobry C., Abdel-Wahab O., Oh P., Haeno H., Buonamici S., et al. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature 2011, 473:230-233.
Kannan S., Sutphin R.M., Hall M.G., Golfman L.S., Fang W., Nolo R.M., et al. Notch activation inhibits AML growth and survival: a potential therapeutic approach. J. Exp. Med. 2013, 210:321-337.
Lobry C., Ntziachristos P., Ndiaye-Lobry D., Oh P., Cimmino L., Zhu N., et al. Notch pathway activation targets AML-initiating cell homeostasis and differentiation. J. Exp. Med. 2013, 210:301-319.
Lobry C., Oh P., Mansour M.R., Look A.T., Aifantis I. Notch signaling: switching an oncogene to a tumor suppressor. Blood 2014, 123:2451-2459.
Perkins N.D. The diverse and complex roles of NF-κB subunits in cancer. Nat. Rev. Cancer 2012, 12:121-132.
Ryan K.M., Ernst M.K., Rice N.R., Vousden K.H. Role of NF-kappaB in p53-mediated programmed cell death. Nature 2000, 404:892-897.
Rocha S., Campbell K.J., Perkins N.D. p53- and Mdm2-independent repression of NF-kappa B transactivation by the ARF tumor suppressor. Mol. Cell 2003, 12:15-25.
Chien Y., Scuoppo C., Wang X., Fang X., Balgley B., Bolden J.E., et al. Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity. Genes Dev. 2011, 25:2125-2136.
Jing H., Kase J., Dörr J.R., Milanovic M., Lenze D., Grau M., et al. Opposing roles of NF-κB in anti-cancer treatment outcome unveiled by cross-species investigations. Genes Dev. 2011, 25:2137-2146.
Bjordahl R.L., Steidl C., Gascoyne R.D., Ware C.F. Lymphotoxin network pathways shape the tumor microenvironment. Curr. Opin. Immunol. 2013, 25:222-229.